Gilead Is UBS's Top Biotechnology Pick, Roden Says

Sept. 10 (Bloomberg) -- Matthew Roden, senior biotechnology analyst at UBS Securities, talks with Bloomberg Industries senior health-care analyst Andrew Berens and Bloomberg First Word health-care journalist Sasha Damouni about the Hepatitis C marketplace including drug development and potential mergers and acquisitions in the space. (Source: Bloomberg)
Square Rival iZettle Raises $67M From Intel and Zouk
00:14 - Today’s "BWest Byte" is $67 million, for how much iZettle, a Swedish payments startup and rival to Jack Dorsey's Square, has raised from Intel and Zouk. Bloomberg's Matt Miller reports on "Bloomberg West." (Source: Bloomberg)
  • What's Next for Flexible Electronic Technology?
  • Facebook Cracks Down on Video Pirates
  • Deep Dive: Is Market Turmoil Hurting Consumer Sentiment?